BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 31125381)

  • 1. Structural analysis of Cytochrome P450 BM3 mutant M11 in complex with dithiothreitol.
    Frydenvang K; Verkade-Vreeker MCA; Dohmen F; Commandeur JNM; Rafiq M; Mirza O; Jørgensen FS; Geerke DP
    PLoS One; 2019; 14(5):e0217292. PubMed ID: 31125381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering bacterial cytochrome P450 (P450) BM3 into a prototype with human P450 enzyme activity using indigo formation.
    Park SH; Kim DH; Kim D; Kim DH; Jung HC; Pan JG; Ahn T; Kim D; Yun CH
    Drug Metab Dispos; 2010 May; 38(5):732-9. PubMed ID: 20100815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glutamate-haem ester bond formation is disfavoured in flavocytochrome P450 BM3: characterization of glutamate substitution mutants at the haem site of P450 BM3.
    Girvan HM; Levy CW; Williams P; Fisher K; Cheesman MR; Rigby SE; Leys D; Munro AW
    Biochem J; 2010 Apr; 427(3):455-66. PubMed ID: 20180779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of residue 87 in substrate selectivity and regioselectivity of drug-metabolizing cytochrome P450 CYP102A1 M11.
    Vottero E; Rea V; Lastdrager J; Honing M; Vermeulen NP; Commandeur JN
    J Biol Inorg Chem; 2011 Aug; 16(6):899-912. PubMed ID: 21567268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Active site substitution A82W improves the regioselectivity of steroid hydroxylation by cytochrome P450 BM3 mutants as rationalized by spin relaxation nuclear magnetic resonance studies.
    Rea V; Kolkman AJ; Vottero E; Stronks EJ; Ampt KA; Honing M; Vermeulen NP; Wijmenga SS; Commandeur JN
    Biochemistry; 2012 Jan; 51(3):750-60. PubMed ID: 22208729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A highly active single-mutation variant of P450BM3 (CYP102A1).
    Whitehouse CJ; Bell SG; Yang W; Yorke JA; Blanford CF; Strong AJ; Morse EJ; Bartlam M; Rao Z; Wong LL
    Chembiochem; 2009 Jul; 10(10):1654-6. PubMed ID: 19492389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insights into regioselective metabolism of mefenamic acid by cytochrome P450 BM3 mutants through crystallography, docking, molecular dynamics, and free energy calculations.
    Capoferri L; Leth R; ter Haar E; Mohanty AK; Grootenhuis PD; Vottero E; Commandeur JN; Vermeulen NP; Jørgensen FS; Olsen L; Geerke DP
    Proteins; 2016 Mar; 84(3):383-96. PubMed ID: 26757175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural and spectroscopic characterization of P450 BM3 mutants with unprecedented P450 heme iron ligand sets. New heme ligation states influence conformational equilibria in P450 BM3.
    Girvan HM; Seward HE; Toogood HS; Cheesman MR; Leys D; Munro AW
    J Biol Chem; 2007 Jan; 282(1):564-72. PubMed ID: 17077084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crystallographic insights into a cobalt (III) sepulchrate based alternative cofactor system of P450 BM3 monooxygenase.
    Panneerselvam S; Shehzad A; Mueller-Dieckmann J; Wilmanns M; Bocola M; Davari MD; Schwaneberg U
    Biochim Biophys Acta Proteins Proteom; 2018 Jan; 1866(1):134-140. PubMed ID: 28739446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Free energy calculations give insight into the stereoselective hydroxylation of α-ionones by engineered cytochrome P450 BM3 mutants.
    de Beer SB; Venkataraman H; Geerke DP; Oostenbrink C; Vermeulen NP
    J Chem Inf Model; 2012 Aug; 52(8):2139-48. PubMed ID: 22765880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insights into an efficient light-driven hybrid P450 BM3 enzyme from crystallographic, spectroscopic and biochemical studies.
    Spradlin J; Lee D; Mahadevan S; Mahomed M; Tang L; Lam Q; Colbert A; Shafaat OS; Goodin D; Kloos M; Kato M; Cheruzel LE
    Biochim Biophys Acta; 2016 Dec; 1864(12):1732-1738. PubMed ID: 27639964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Electron transfer in flavocytochrome P450 BM3: kinetics of flavin reduction and oxidation, the role of cysteine 999, and relationships with mammalian cytochrome P450 reductase.
    Roitel O; Scrutton NS; Munro AW
    Biochemistry; 2003 Sep; 42(36):10809-21. PubMed ID: 12962506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel haem co-ordination variants of flavocytochrome P450BM3.
    Girvan HM; Toogood HS; Littleford RE; Seward HE; Smith WE; Ekanem IS; Leys D; Cheesman MR; Munro AW
    Biochem J; 2009 Jan; 417(1):65-76. PubMed ID: 18721129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Control of the stereo-selectivity of styrene epoxidation by cytochrome P450 BM3 using structure-based mutagenesis.
    Huang WC; Cullis PM; Raven EL; Roberts GC
    Metallomics; 2011 Apr; 3(4):410-6. PubMed ID: 21240430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of protein plasticity in computational rationalization studies on regioselectivity in testosterone hydroxylation by cytochrome P450 BM3 mutants.
    de Beer SB; van Bergen LA; Keijzer K; Rea V; Venkataraman H; Guerra CF; Bickelhaupt FM; Vermeulen NP; Commandeur JN; Geerke DP
    Curr Drug Metab; 2012 Feb; 13(2):155-66. PubMed ID: 22208530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of engineered cytochrome P450 mutants as biocatalysts for the synthesis of benzylic and aromatic metabolites of fenamic acid NSAIDs.
    Venkataraman H; Verkade-Vreeker MC; Capoferri L; Geerke DP; Vermeulen NP; Commandeur JN
    Bioorg Med Chem; 2014 Oct; 22(20):5613-20. PubMed ID: 24999003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydroxylation of non-substituted polycyclic aromatic hydrocarbons by cytochrome P450 BM3 engineered by directed evolution.
    Sideri A; Goyal A; Di Nardo G; Tsotsou GE; Gilardi G
    J Inorg Biochem; 2013 Mar; 120():1-7. PubMed ID: 23262457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of human metabolites of 7-ethoxycoumarin by bacterial cytochrome P450 BM3.
    Kim DH; Kim KH; Kim DH; Liu KH; Jung HC; Pan JG; Yun CH
    Drug Metab Dispos; 2008 Nov; 36(11):2166-70. PubMed ID: 18669587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Key mutations alter the cytochrome P450 BM3 conformational landscape and remove inherent substrate bias.
    Butler CF; Peet C; Mason AE; Voice MW; Leys D; Munro AW
    J Biol Chem; 2013 Aug; 288(35):25387-25399. PubMed ID: 23828198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of drug metabolising mutants of cytochrome P450 BM3 (CYP102A1) as biocatalysts for the generation of reactive metabolites.
    Damsten MC; van Vugt-Lussenburg BM; Zeldenthuis T; de Vlieger JS; Commandeur JN; Vermeulen NP
    Chem Biol Interact; 2008 Jan; 171(1):96-107. PubMed ID: 17996858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.